drugset / Trial / NCT03881488
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Phase 1
Completed
100 enrolled
Compass Therapeutics
IQVIA Pty Ltd · collabMerck, Sharp & Dohme, LLC, Rahway, NJ USA · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving an approved PD-1 or PD-L1 inhibitor. The study will be conducted in 2 treatment arms (Monotherapy Arm 1 and Combination Arm 2). Each arm will have two parts: Part 1 Dose Escalation and Part 2 Dose Expansion.
Timeline
- Start
- 2019-05-17
- Primary completion
- 2025-05-21
- Completion
- 2025-05-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CTX-471 | Unknown | 0.3 mg/kg | Intravenous |
| Subject | CTX-471 | Unknown | 0.6 mg/kg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 400 mg | Intravenous |